BENGALURU/HYDERABAD (Reuters) – Indian generic drugmaker Cipla posted a bigger-than-expected 32% rise in third-quarter profit on Monday, driven by strong performance in its North American business.
Consolidated net profit climbed to 10.56 billion Indian rupees ($127.1 million) in the quarter ended Dec. 31, beating analysts’ average estimate of 10.43 billion rupees, as per LSEG data.
($1 = 83.1050 Indian rupees)
(Reporting by Kashish Tandon and Varun Vyas in Bengaluru, Rishika Sadam in Hyderabad; Editing by Anil D’Silva)
Comments